Skip to Main Content

Latest News

Yale Scientists Win NIH Awards for Pioneering Work

Yale School of Medicine’s Valentina Greco and Marina R. Picciotto are among the 11 recipients of the National Institutes of Health’s Pioneer Award, which recognizes scientists who have a history of creative research and who show promise in originating “pioneering approaches to major challenges.” Greco and Picciotto will each receive $3.5 million dollars of funding over the course of five years. In addition, four young Yale scientists will receive the NIH’s Innovator Award.

Read more
  • Mammals’ Enhanced Capacity to See Emerges Early in Development

    All vertebrates possess a primitive network in which the retina sends signals directly to the superior colliculus, an area of the brain that processes visual stimuli. In a more recently evolved pathway, signals from the retina are received in the thalamus and are relayed to the cortex, the brain’s seat of higher-order thinking.

    Read more
  • What's Killing America's Vapers?

    Marina Picciotto, PhD, Charles B.G. Murphy Professor of Psychiatry and Professor in the Child Study Center, of Neuroscience and of Pharmacology, was a guest on the Australian television news program Planet America. She discussed the science around the recent outbreak of vaping-related illnesses on an episode titled, "What's Killing America's Vapers?"

    Read more
  • Horwich Is Co-recipient of $3 Million Breakthrough Prize

    Arthur L. Horwich, MD, Sterling Professor of Genetics and professor of pediatrics, and his colleague F. Ulrich Hartl, from the Max Planck Institute, will share a 2020 Breakthrough Prize. This prize was developed by Sergey Brin, Mark Zuckerberg, Jack Ma, and Yuri Milner, together with their families, to honor the most accomplished life scientists.

    Read more
  • Nasal Spray Offers Hope for Severly Depressed Patients

    John H. Krystal, MD, Chair of the Yale Department of Psychiatry, spoke to the Connecticut Health I-Team for a story about the new nasal spray Spravato, which after receiving Food and Drug Administration approval in March is being prescribed for treatment-resistant depression. Krystal is best known for leading the discovery of the rapid antidepressant effects of ketamine in depressed patients. Spravato's chemical name is esketamine, a derivative of ketamine.

    Read more